Comparative Pharmacology
Head-to-head clinical analysis: ARRANON versus LYSODREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARRANON versus LYSODREN.
ARRANON vs LYSODREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purine nucleoside analog; after intracellular phosphorylation to ara-GTP, it incorporates into DNA, inhibits DNA synthesis, and induces apoptosis in T-cell progenitors.
Adrenocorticolytic agent; causes adrenal cortical necrosis and suppresses adrenal steroidogenesis, especially glucocorticoids and mineralocorticoids.
2600 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
Oral, initial dose 2-6 g/day divided in 3-4 doses, increase gradually to 8-10 g/day. Maximum dose 18 g/day.
None Documented
None Documented
Terminal elimination half-life of nelarabine is approximately 30 minutes; the active metabolite ara-G has a terminal half-life of approximately 20-24 hours. Clinically, this supports daily dosing in cycles.
18-159 days; clinical context: during chronic therapy, steady-state may not be reached for 3-6 months.
Nelarabine is extensively metabolized to ara-G; elimination is primarily renal: ~27% as parent drug and 30-50% as ara-G in urine. Fecal excretion accounts for <5% of administered dose.
Primarily renal excretion of metabolites; about 10% as unchanged drug. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antineoplastic
Antineoplastic